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http://www.biomedcentral.com/1746-6148/10/184RESEARCH ARTICLE Open AccessThe long-acting COX-2 inhibitor mavacoxib
(Trocoxil™) has anti-proliferative and pro-apoptotic
effects on canine cancer cell lines and cancer
stem cells in vitro
Lisa Y Pang*, Sally A Argyle, Ayako Kamida, Katherine O’Neill Morrison and David J ArgyleAbstract
Background: The NSAID mavacoxib (Trocoxcil™) is a recently described selective COX-2 inhibitor used for the
management of inflammatory disease in dogs. It has a long plasma half-life, requiring less frequent dosing and
supporting increased owner compliance in treating their dogs. Although the use of NSAIDs has been described in
cancer treatment in dogs, there are no studies to date that have examined the utility of mavacoxib specifically.
Results: In this study we compared the in vitro activity of a short-acting non-selective COX inhibitor (carprofen) with
mavacoxib, on cancer cell and cancer stem cell survival. We demonstrate that mavacoxib has a direct cell killing
effect on cancer cells, increases apoptosis in cancer cells in a manner that may be independent of caspase activity,
and has an inhibitory effect on cell migration. Importantly, we demonstrate that cancer stem cells derived from
osteosarcoma cell lines are sensitive to the cytotoxic effect of mavacoxib.
Conclusions: Both NSAIDs can inhibit cancer cell proliferation and induce apoptosis in vitro. Importantly, cancer
stem cells derived from an osteosarcoma cell line are sensitive to the cytotoxic effect of mavacoxib. Our results
suggest that mavacoxib has anti-tumour effects and that this in vitro anti-cancer activity warrants further study.
Keywords: Mavacoxib, COX-2, Cancer stem cells, Osteosarcoma, CanineBackground
Cyclooxygenase (COX) is a key enzyme in the synthesis of
prostaglandins from arachidonic acid. There are two iso-
forms of cylooxygenase: COX-1 and COX-2. COX-1 is con-
stitutively expressed in almost all tissues, whereas COX-2 is
predominantly induced in response to certain stimuli in-
cluding growth factors and pro-inflammatory cytokines [1].
Overexpression of COX-2 has been reported in diseases as-
sociated with inflammation and various cancers [2,3]. Fur-
thermore, there has been increasing evidence that COX-2
overexpression is associated with tumourigenesis [4], angio-
genesis [5], resistance to apoptosis, cancer cell proliferation
and metastasis [6,7]. COX-2 protein expression has been
associated with a poor prognosis in human breast cancer
[8], colon cancer [9], malignant mesothelioma [10], head* Correspondence: lisa.pang@ed.ac.uk
The Royal (Dick) School of Veterinary Studies and The Roslin Institute, The
University of Edinburgh, Easter Bush, Edinburgh, Midlothian EH25 9RG, UK
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.and neck squamous cell carcinoma [11], and chronic mye-
logenous leukemia [12].
In recent years the traditional stochastic model of cancer
development has been challenged by a new model, which
implicates cancer stem cells (CSC) as the subpopulation of
cancer cells that drives tumour growth, recurrence and
metastasis [13]. CSCs share several characteristics with
embryonic and somatic stem cells including self-renewal
and differentiation abilities, and represent a small fraction
of the cellular population of the tumour [13]. The role of
CSCs was initially established in leukaemia, and more re-
cently in solid tumours including melanomas [14,15], glio-
blastomas [16], and epithelial cancers [17-21]. Increasing
evidence has implicated CSCs in tumourigenesis and re-
sponse to treatment of many tumour types. Significantly,
the resistance of these cells to conventional chemothera-
peutic regimes suggests that CSCs play a major role in
drug resistance and treatment failure [22]. Interestingly,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and breast CSCs and constituted part of an eight-gene
signature that correlated with breast cancer patient
survival [24].
Non-steroidal anti-inflammatory drugs (NSAIDs) in-
hibit the COX enzyme thereby reducing the production
of prostaglandins. NSAIDs are therefore widely used to
reduce the clinical signs associated with inflammation.
Moreover, increasing evidence from animal models has
demonstrated the anti-tumoural and chemopreventative
effects that NSAIDs have on several tumours, including
intestinal, breast, skin, lung, and bladder tumours [25-28].
In addition, Thun et al. (1991) reported that low dose
NSAIDs reduced relative risk of colorectal cancer [29],
and subsequent studies support increasing evidence that
NSAIDs significantly reduce colon polyp formation and
recurrence [30,31]. Currently, there are several ongoing
human clinical trials utilising NSAIDs as cancer therapeu-
tics [32,33].
In dogs, overexpression of COX-2 and prostaglandin E2
(PGE2) have been identified in a wide variety of cancers,
including transitional carcinoma of urinary bladder [34],
lymphoma, mammary gland tumours and osteosarcoma
[35-37]. As an example, previous studies have shown that
COX-2 is not normally expressed in canine bone, but that
around 77% of osteosarcomas are positive for COX-2 ex-
pression [38]. The suggestion that this makes COX-2 and
the prostaglandin PGE2 promising therapeutic targets, is
supported by the demonstrable therapeutic benefits of
using NSAIDs in tumours that overexpress COX-2, such
as prostatic carcinoma [39] and osteosarcoma [40]. Con-
currently, use of the NSAID piroxicam is a standard rec-
ommendation of treatment for dogs with transitional cell
carcinoma. In a pilot study, it was found that 20 percent
of dogs with bladder tumours treated with piroxicam
alone had a partial or complete response [41].
Mavacoxib (Trocoxil™) is a member of the coxib class
of selective COX-2 inhibitors and is approved in the
European Union for the treatment of pain and inflam-
mation in canine osteoarthritis, where continuous treat-
ment exceeding 1 month is indicated [42]. Mavacoxib is
unique among NSAIDs because its combination of low
clearance and relatively large apparent volume of distri-
bution mean that it has a plasma half-life that is much
longer than those of other NSAIDs, leading to a much
reduced frequency of dosing. The potential benefits of
using mavacoxib clinically are therefore high, but to
date, there have been no studies evaluating the anti-
cancer effects of this drug.
In this study we evaluated the anti-cancer effects of
mavacoxib and compared this to another clinically im-
portant NSAID, carprofen (a non-selective COX in-
hibitor). Using a panel of canine cancer cell lines we
demonstrate that both drugs can inhibit cancer cellproliferation in vitro and we show that both drugs in-
duce apoptosis in cancer cells in a manner that may be
independent of caspase activity. Furthermore, mava-
coxib, but not carprofen, is cytotoxic to cancer stem
cells derived from osteosarcoma cell lines.
Results
Mavacoxib (Trocoxil™) inhibits cell proliferation of canine
cancer cell lines
A panel of canine cell lines, including CPEK (normal
epidermal keratinocyte), D17 (osteosarcoma), KTOSA5
(osteosarcoma), CSKOS (osteosarcoma), J3T (glioma), 3132
(lymphoma), C2-S (mast cell tumour) and SB (hemangio-
sarcoma) were used to determine the effect of NSAIDs on
cell viability (Figure 1). Both carprofen and mavacoxib
suppressed cancer cell proliferation effectively in a dose
dependent manner, however mavacoxib showed a superior
effect in the majority of the cell lines tested (p < 0.05), with
the exception of SB cells (Figure 1). C2-S showed the great-
est sensitivity to mavacoxib with an IC50 value of 29.3 μM,
whereas 3132 cells showed the greatest sensitivity to car-
profen with an IC50 value of 63.46 μM (Table 1).
Mavacoxib induces apoptosis in cancer cells and is
independent of caspase activation
To determine the mechanism by which these NSAIDs re-
duce cell viability, we assayed treated cells for evidence of
apoptosis by utilizing Annexin V staining, and explored
expression of mediators of apoptosis including caspase ac-
tivity and levels of Bax and Bcl2. In both KTOSA5 and
CSKOS cells, we demonstrated a dose-dependent in-
crease in the percentage of apoptotic cells when either
carprofen or mavacoxib were used. Interestingly, both
drugs had little effect on non-cancerous CPEK cells,
even at high doses of the inhibitor. Both mavacoxib and
carprofen had a significant time-dependent and dose-
dependent effect on KTOSA5 and CSKOS apoptosis
(Figure 2). Generally, the percentage of cells undergoing
apoptosis was highest in cells treated with 100 μm
NSAIDs for 48 hours, although CSKOS cells were
equally effected by 50 μm and 100 μm mavacoxib at
48 hours (Figure 2). To explore the effects on apoptosis
further, we investigated the ability of both drugs to
cause activation of caspase-2, caspase-8, caspase-9 and
caspase-3 following 48 hours of treatment with either
mavacoxib or carprofen. We demonstrated no signifi-
cant difference between the enzyme activity of the initi-
ator caspases -2, -8, -9 and the main effector caspase -3
in cells treated or not treated, suggesting that apoptosis
in these cells may be caspase-independent (Additional
file 1: Figure S1).
When we then assayed the treated cells for levels of
Bax or Bcl2, we found that treatment stimulated Bcl2
but had no effect on basal Bax levels. Treatment of cells
Figure 1 Mavacoxib inhibits cells proliferation of canine cancer cell lines. Normal keratinocytes (CPEK); osteosarcoma (D17, KTOSA5, CSKOS);
glioma (J3T); lymphoma (3132); mast cell tumour (C2-S); and haemangiosarcoma (SB) cell lines were treated with the indicated doses of either
mavacoxib or carprofen and cell viability was assayed 48 hours after treatment. Red line represents mavacoxib. Blue line represents carprofen.
*p <0.05 indicate a significant difference between mavacoxib and carprofen at the indicated concentration by a student’s t-test.
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of the pro-survival Bcl2 protein, whereas the level of the
pro-apoptotic Bax protein was unchanged. These results
were consistent in all cell lines tested (Figure 3) and in-
dicate that cell death induced by NSAID treatment does
not involve mitochondrial apoptosis.Mavacoxib has cell-type dependent effects on cell invasion
The invasion index (%) was calculated for cells treated
with either carprofen or mavacoxib. Migrated cells were
counted using the transwell assay as described in materials
and methods. In the CSKOS cell line, there was no signifi-
cant difference between the control, untreated cells and
Table 1 Determination of IC50 values for mavacoxib and
carprofen in normal keratinocytes (CPEK); osteosarcoma
(D17, KTOSA5, CSKOS); glioma (J3T); lymphoma (3132); mast
cell tumour (C2-S); and haemangiosarcoma (SB) cell lines
IC50
Cell type Mavacoxib Carprofen
CPEK 87.1 μM 226.6 μM
D17 152.7 μM 225.6 μM
KTOSA5 93.4 μM 172.1 μM
CSKOS 107.8 μM 167 μM
J3T 68.4 μM 239.8 μM
3132 36.5 μM 63.5 μM
C2-S 29.3 μM 93.5 μM
SB 63.5 μM 70.4 μM
All measurements were made in triplicate.
Figure 2 Effects of NSAIDs on apoptosis. CPEK, CSKOS, and KTOSA5 cell
mavacoxib. Annexin V-FITC staining was analysed by FACS 24 hours and 48
quantified. Ÿ p = 0.02, ★ p = 0.01, ♯ p = 0.002, * p < 0.001 by comparing the
untreated control by a student’s t-test.
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mavacoxib there was significant (p < 0.001) inhibition of
invasion that was dose dependent. KTOSA5 cells demon-
strated a similar pattern to CSKOS cells, where the invasion
index was unaffected at 50 μM carprofen, but significantly
decreased at doses of 100 μM (p = 0.024). Treatment with
either 50 μM or 100 μM mavacoxib, showed significant in-
hibition (p < 0.02) of invasion (Figure 4). There was no clear
inhibition in J3T with either carprofen or mavacoxib treat-
ment (Figure 4).
Mavacoxib inhibits cell survival of putative cancer
stem cells
We have previously isolated cancer stem cells from canine
osteosarcoma cell lines [43]. As NSAIDs are used as a pal-
liative treatment for dogs with osteosarcoma [44], wes were treated with the indicated doses of either carprofen or
hours after treatment. The percentage of Annexin V positive cells was
indicated drug concentration at the indicated time point to the
Figure 3 Carprofen and mavacoxib treatment stimulates Bcl2
and has no effect on basal Bax levels Cells were treated with
the indicated dose of either carprofen (C) or mavacoxib (M).
Cells were harvested 48 hours post-treatment.
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the cancer stem cell population of KTOSA5 and CSKOS
cell lines. Cells were magnetically sorted for expression of
the cancer stem cell marker, CD34 (data unpublished),
and assayed for cell viability after treatment with either
mavacoxib or carprofen. There was no significant differ-
ence between CD34- and CD34+ cells. As before, both
mavacoxib and carprofen suppressed cancer cell prolif-
eration effectively in a dose dependent manner, however
mavacoxib was more effective at lower concentrations
(Figure 5). For example, KTOSA5 CD34+ cells treated
with mavacoxib had an IC50 value of 36.03 μM, whereas
the same cells treated with carprofen had an IC50 value
of 49.6 (Table 2).
A colony formation assay was used to determine the ef-
fect of NSAID treatment on cell reproductive death. Here,
KTOSA5 and CSKOS cells were sorted for CD34 and
treated with either mavacoxib or carprofen. As before,both cell lines showed no difference between CD34- and
CD34+ cells. In KTOSA5 cells, treatment with 50 μM
mavacoxib significantly (p < 0.001) decreased the number
of colonies formed compared to untreated cells, and no
colonies were formed after treatment with 100 μM mava-
coxib. In contrast, treatment with 50 μM carprofen had
no effect on the colony forming ability of KTOSA5 cells,
and treatment with 100 μM carprofen only inhibited col-
ony formation by approximately 20% (Figure 6A). Similar
results were obtained for the CSKOS cell line (Figure 6B).
This data indicates that the long-acting COX-2 inhibitor,
mavacoxib is a more effective cytotoxic agent than the
short-acting non-selective COX inhibitor carprofen.
Discussion
NSAIDs can be broadly divided into non-selective inhib-
itors of COX indicating that they inhibit both COX-1
and COX-2 or they can be COX-2 selective. Carprofen
falls into the former category inhibiting both COX-1 and
COX-2. In addition it is suggested that carprofen may
have additional anti-inflammatory mechanisms of action
such as inhibition of fatty acid amide hydrolase. In con-
trast mavacoxib is COX-2 selective, a characteristic of the
coxib class of NSAIDs. Meloxicam, although not a coxib,
is also considered to be relatively COX-2 selective [45].
When used for its anti-inflammatory properties the
prolonged half-life for mavacoxib supports the approved
regimen in which doses are separated by 2–4 weeks. In in-
flammatory conditions, compliance with this regimen is
improved when compared to once-daily NSAID treatment
[46], and because of the prolonged half-life, a continuous
therapeutic response may be more likely in instances when
there are problems with dosing, such as a delay in drug
administration. Because of the relatively long half-life of
mavacoxib, a regimen with a non-constant dosing interval
(i.e. 2 weeks between the first two doses but with a
maintenance 4 week interval) is used for rapid attain-
ment of steady-state concentrations. With this regimen,
plasma mavacoxib concentrations are relatively con-
stant (0.52-1.11 μg/ml). In contrast carprofen has a
more typical NSAID half-life in the dog supporting once
daily drug administration.
In this current study we have demonstrated that mava-
coxib, a COX-2 inhibitor, induced significant cell growth
arrest and apoptosis in a panel of canine cancer cell lines,
including D17 (osteosarcoma), KTOSA5 (osteosarcoma),
CSKOS (osteosarcoma), J3T (glioma), 3132 (lymphoma),
C2-S and SB (hemangiosarcoma). In comparison to car-
profen, mavacoxib exhibited superior inhibition of cancer
cell viability with IC50 values 3.5-fold to 1.5-fold higher,
depending on the cell line. Interestingly, neither drug
induced apoptosis in normal cells (CPEK). Whereas, in
the osteosarcoma cell lines tested, both carprofen and
mavacoxib induced a dose-dependent increase in the
Figure 4 NSAID treatment has cell type dependent effects on cell invasion. Cells were treated with the indicated dose of either carprofen
(C) or mavacoxib (M). Cells were counted 48 hours post-treatment. ↑ p = 0.024 by Mann–Whitney test, ★ p = 0.007, ♯ p = 0.002, * p < 0.001 by a
student’s t-test.
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cating that cancer cells may be more sensitive to the kill-
ing effect of COX inhibition compared to normal cells.
Apoptosis is a conserved cell death mechanism essential
for normal development and tissue homeostasis. Clas-
sically, apoptotic cell death is characterized by caspase
activation, down-regulation of Bcl2 and up-regulation
of pro-apoptotic Bax [47]. Here, we show that apoptosis
induced by either mavacoxib or carprofen is independ-
ent of the initiator caspases 2, 8 and 9, and the effector
caspase 3. We also show that all the cell lines tested
have a high basal level of Bax, which is not induced by
increasing doses of either mavacoxib or carprofen. Con-
currently, there is a dose-dependent increase in levels of
anti-apoptotic Bcl2. Previous studies have shown that
both apoptotic and anti-apoptotic factors are up-
regulated in human tumours, and this leads to an im-
pairment of the apoptotic signaling pathway and can
confer resistance to apoptosis [48]. However, we ob-
served this pattern in normal cells that have a function-
ing apoptotic pathway. We also confirmed that cell
death was due to apoptosis and not necrosis. Caspase-
independent and Bax-independent cell death has previ-
ously been characterised [49]. Further investigation is
required to determine if mavacoxib induces caspase-
independent cell death in canine cancer cell lines. In
human studies of osteosarcoma and gastric cancer cell
lines treated with meloxicam and SC236 (a potent
COX-2 selective inhibitor) respectively, no induction ofBax protein was demonstrated [35,50]. Naruse et al.
(2006) discussed that the COX-2 selective NSAID meloxi-
cam may affect a Bax-independent apoptotic pathway,
which is yet to be elucidated [35].
We also demonstrated that in the osteosarcoma cell
lines, KTOSA5 and CSKOS, high doses of mavacoxib
are better at inhibiting invasiveness compared to carpro-
fen. In the J3T glioma cell line there was no difference in
invasiveness compared to control, indicating that COX-2
may have cell type specific effects. The mechanism of
this inhibition requires further investigation, but it sug-
gests that mavacoxib may have potential therapeutic bene-
fits. Previous studies have demonstrated that COX-2
derived PGE2 activates CD44 and MMP-2, and in turn
stimulates invasiveness of lung cancer cells in vitro [51]. In
addition, COX-2 inhibition of the human osteosarcoma
cell line, MG-63, by meloxicam can also inhibit invasive-
ness [35]. The role of COX-2 in the tumour microenviron-
ment should also be considered; Williams et al. (2000)
showed that the tumours grown in COX-2-null mice had
decreased growth, as well as vascular density, compared to
wild type mice [52], suggesting that both host cells and
tumour cells are affected by COX-2 expression levels.
To fully determine the anti-proliferative effect of COX-2
inhibition on canine cancer, it is fundamental to study the
effect of COX-2 inhibition on the cancer stem cell popula-
tion. Cancer stem cells are a small subpopulation of cells
that can influence initiation, recurrence and chemoresis-
tance of a tumour [13]. As we have previously isolated
Figure 5 Sensitivity to NSAIDs is not affected by CD34 status in (A) KTOSA5 cells or (B) CSKOS cells. Cells were treated with the indicated
doses of either mavacoxib or carprofen and cell viability was assayed 48 hours after treatment.
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and NSAIDs are used as a palliative treatment for dogs
with osteosarcoma, we used the canine osteosarcoma cell
lines, to look at the effect of COX-2 inhibition with mava-
coxib. Cancer stem cells isolated from these cell lines areTable 2 Determination of IC50 values for mavacoxib and
carprofen in KTOSA5 and CSKOS cells sorted for CD34
protein expression
IC50
Cell type Drug CD34- CD34+
KTOSA5 Mavacoxib 38.63 μM 27.37 μM
KTOSA5 Carprofen 42.94 μM 44.87 μM
CSKOS Mavacoxib 37.62 μM 36.03 μM
CSKOS Carprofen 55.86 μM 49.6 μM
All measurements were made in triplicate.inherently more resistant to the cytotoxic effect of the
anthracycline antibiotic, doxorubicin (data unpublished).
Here, we show that there is no significant difference be-
tween cancer cells and putative cancer stem cells. This is
significant as it shows that cancer stem cells are not resist-
ant to COX-2 inhibition. As before, mavacoxib is more ef-
fective at killing cells at a lower concentration than
carprofen.
We also determined the long-term effect of COX-2 in-
hibition on replicative cell death of both cancer and cancer
stem cells. Significantly, mavacoxib dramatically decreased
the colony forming ability in a dose-dependent manner in
both cell populations, whereas carprofen only had a modest
effect. Mavacoxib is a long-acting COX-2 inhibitor with a
relatively long plasma half-life compared to carprofen, and
this may account for the difference in colony forming abil-
ity. As we have shown here, mavacoxib is more effective
Figure 6 Mavacoxib is better than carprofen at inhibiting colony forming ability of KTOSA5 cells (A) and CSKOS cells (B) independent
of CD34 status. Cells were treated with the indicated doses of either mavacoxib or carprofen and colony formation was assayed. Number of
colonies per plate was counted. Representative images are shown. * p = 0.001, ** p < 0.001, ♯ p = 0.007, ★ p < 0.001, ★★ p = 0.002 by a
student’s t-test.
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and cancer stem cells.
Mavacoxib is closely related to the human drug, cele-
coxib. Previous studies have shown that putative cancer
stem cells isolated from human glioma cell lines express
constitutively high levels of COX-2 protein, which are posi-
tively correlated with radioresistance. Treatment with cele-
coxib enhanced radiosensitivity of glioma stem cells and
suppressed the expression of angiogenic and stemness-
related genes [53]. To date, the molecular mechanism bywhich the COX-2 inhibitors, celecoxib and mavacoxib,
exert their anti-tumour effect on the cancer stem cell popu-
lation is yet to be elucidated. Further studies should be con-
ducted to determine if mavacoxib also has synergistic
effects with other chemotherapeutic agents. The data pre-
sented here demonstrates that the anti-proliferative effects
of mavacoxib are effective on a range of canine cancer cell
types and that the therapeutic potential of mavacoxib, ei-
ther as a single agent or as a multimodal therapy, should be
further investigated.
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Our study provides the first evidence that mavacoxib is an
effective anti-tumour agent. Mavacoxib can inhibit cell pro-
liferation and invasiveness better than carprofen. Import-
antly, mavacoxib can inhibit cancer stem cell survival in an
in vitro osteosarcoma model. Therefore, mavacoxib could
be a potential candidate for the treatment of canine cancer
and further studies of its clinical use are now required.
Methods
Cell culture
The KTOSA5 cell line was derived from an osteosar-
coma affecting the right hind limb of an 8-year-old,
chemotherapy naïve, female entire Rottweiler (approved
by the University of Edinburgh Veterinary Ethical Review
Committee). KTOSA5 (osteosarcoma), CSKOS (osteo-
sarcoma), J3T (glioma) cell lines were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, Paisley,
UK) supplemented with 10% fetal bovine serum and
100 μg/ml streptomycin (Invitrogen, Paisley, UK). D17
(osteosarcoma), C2-S (mast cell tumour) and SB (heman-
giosarcoma) cells were grown in DMEM-GlutaMAX™
(Invitrogen) supplemented with 10% fetal bovine serum
and 100 μg/ml streptomycin. 3132 (lymphoma) cells were
grown in RPMI medium 1640 (Invitrogen) supplemented
with 10% fetal bovine serum and 100 μg/ml streptomycin.
CPEK (normal epidermal keratinocyte) were cultured in
CnT-09 epidermal keratinocyte medium (CELLnTEC,
Bern, Switzerland). All cell cultures were maintained at
37°C in a humidified CO2 incubator.
Magnetic cell sorting
Cells were labelled with CD34 microbeads and sorted
using the Miltenyi Biotec CD34 cell isolation kit according
to the manufacturer’s protocol (Miltenyi Biotec, Surrey,
UK). Briefly, cells were resuspended in 300 μl PBS solution
(pH 7.2, 0.5% BSA, 2 mM EDTA) per 108 cells. Then
blocking reagent FcR (100 μl/108 cells; Miltenyi Biotec,
Surrey, UK) and CD34 microbeads (100 μl/108 cells) were
added and mixed at 4°C for 30 minutes with rotation.
Cells were washed in 20× volume with PBS solution. The
pellet was resuspended in 500 μl PBS solution and added
to a pre-washed magnetic separation (LS) column on the
magnetic holder. The column was washed four times and
the collected cells were designated as the negative fraction.
The column was removed from the magnetic holder and
the positive fraction was collected.
Cell viability assay
To determine cell viability, CellTiter-Glo® Luminescent
Cell Viability Assay kit (Promega, Madison, WI, USA) was
used according to manufacturer’s instructions. Briefly, 500
cells were seeded per well in a 96-well plate, in triplicate.
Cells were incubated for 24 h at 37°C, 5% CO2. Drugswere applied at a range of concentrations (0 μM – 5 mM)
and incubated for 48 h. The plate was equilibrated at room
temperature for 30 min and 100 μl of CellTiter-Glo® re-
agent was added to each well. Luminescence was recorded
by a luminometor (Viktor3, PerkinElmer, Massachusetts,
USA). IC50 values were calculated from three replicates
using GraphPad Prism version 5 software (GraphPad Soft-
ware Inc., San Diego, CA).
Colony formation assay
Cells were trypsinised into single cells and seeded at 500
cells/10 cm plate. The cells were incubated with appro-
priate doses of either mavacoxib or carprofen whilst in
suspension. Plates were incubated at 37°C in a humidified
CO2 incubator until colonies were visible. Growth media
was changed once a week. The colonies were fixed by in-
cubating with ice-cold methanol for 5 minutes at room
temperature. Colonies were stained with Giemsa stain
(Invitrogen, Paisley, UK) according to the manufacturer’s
instructions and the number of colonies were counted.
Caspase profiling assay
Activation of caspase-2, caspase-8, caspase-9 and caspase-
3 on indicated drug treatments was determined using a
caspase profiling plate (Clontech lab., CA, USA) according
to the manufacturer’s instructions. Briefly, cells were
grown until 60-70% confluent, then treated with either
carprofen or mavacoxib (50 μM and 100 μM), and incu-
bated for 48 h at 37°C, 5% CO2. Untreated cells were also
prepared as a control for each cell line. After treatment,
2 × 105 cells were prepared per well, lysed in cold 1× Cell
Lysis Buffer (50 μl/2 × 105 cells) and incubated for 10 min
on ice. The plates were preincubated with 50 μl of 2× Re-
action buffer (mixed with 0.1 M DTT) to each well for
5 min at 37°C, 5% CO2. Cell lysates were transferred to
each well and incubated for 2 h at 37°C, 5% CO2. Caspase
activities were read using a fluorescent plate reader (exci-
tation: 380 nm, emission: 460 nm) (Viktor3, PerkinElmer,
Massachusetts, USA).
Annexin V assay
The BD FITC Annexin V Apoptosis Detection kit (BD
PharMingen, San Diego, CA) was used to determine the ef-
fect of carprofen or mavacoxib treatment on the level of
apoptosis. The Annexin V analysis allows monitoring of
changes in necrosis, early apoptosis and late apoptosis. The
assay was performed according to the manufacturer’s in-
structions. Briefly, cells were grown until 60-70% confluent
and treated with either carprofen or mavacoxib at final con-
centrations of 50 μM and 100 μM. Untreated cells were
used as controls for each cell line. Cells were treated for
24 h and 48 h at 37°C, 5% CO2. Subsequently, cells were
washed twice with cold PBS, trypsinized and resuspended
in 1 ml of 0.1% BSA containing PBS. 1 × 105 cells/ml and
Pang et al. BMC Veterinary Research 2014, 10:184 Page 10 of 11
http://www.biomedcentral.com/1746-6148/10/184were then stained with Annexin V FITC and propidium
iodide for 15 min in the dark. The CyAn ADP analyser
(Beckman Coulter Inc. CA, USA) was used and the data
was analyzed using Summit v4.3 software.
Migration and invasion assay
To evaluate the effect of carprofen and mavacoxib on
the metastatic potential of the cell lines, motility and in-
vasiveness were analysed using a transwell migration
and invasion assay. CPEK, KTOSA5, CSKOS, D17 and
J3T cells were grown to 60-70% confluency and then
treated with carprofen or mavacoxib at concentrations
of 50 μM and 100 μM. Cell lines were incubated for
48 h at 37°C, 5% CO2. Subsequently, cells were detached
and re-suspended in FBS-free medium. For the migra-
tion assay, 2.5 × 104 cells in 500 μl volume were plated
on the top chamber with a non-coated polycarbonate
membrane with 8.0 μm pore size (BD Bioscience,
Bedford, MA, USA) in duplicate. Medium with 10% FBS
was added in the lower chamber as a chemoattractant.
After incubation for 24 h, the cells that migrated to the
lower surface of the polycarbonate membrane were fixed
with methanol for 1 min, followed by Giemsa stain for
15 min. The cells which did not migrate through the
pores, were mechanically removed by a cotton swab
moistened with the medium. The mean number of mi-
grated cells was counted in 5 random fields of each mem-
brane. The invasion assay was performed as for the
previously described migration assay, except that the
transwell inserts consist of Matrigel-coated polycarbonate
membranes with 8.0 μm pore size. Matrigel mimics
the basement membrane in vitro and provides a bar-
rier to non-invasive cells. Data is expressed as the per-
cent invasion calculated by the following formula;
% Invasion = (Mean number of cells invading/Mean num-
ber of cells migrating) × 100.Protein detection
Cells were lysed in urea lysis buffer (7 M urea, 0.1 M
DTT, 0.05% Triton X-100, 25 mM NaCl, 20 mM Hepes
pH 7.5). Equal amounts of protein were separated by
SDS polyacrylamide gel electrophoresis (SDS PAGE),
transferred to Hybond-C nitrocellulose membrane
(Amersham Pharmacia Biotech, Buckinghamshire, UK)
and hybridised to an appropriate primary antibody and
HRP-conjugated secondary antibody for subsequent
detection by ECL. Primary antibody against β-actin
was purchased from Abcam (Cambridge, UK). Anti-
bodies against Bax and Bcl2 were purchased from
Santa Cruz Biotechnology (CA, USA). The secondary
antibodies, HRP-conjugated rabbit anti-mouse IgG and
swine anti-rabbit IgG, were obtained from DakoCyto-
mation (Glostrup, Denmark).Statistical analysis
Data were expressed as mean ± SD. Statistical analysis
was performed with Minitab® statistical software (PA,
USA) using analysis of variance and student’s t test or
Mann–Whitney test. The criterion for significance was
p < 0.05 for all comparisons.
Additional file
Additional file 1: Figure S1. NSAID treatment has cell-type dependent
effects on caspase activity. Cells were treated with either 50 μM or
100 μM carprofen (C) or mavacoxib (M) for 48 hours. Caspase activity was
determined using the apoalert caspase assay kit (Calbiochem). Blue bars
represents carprofen treatment. Red bar represents mavacoxib treatment.
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